Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rotoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 8/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 8/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 8/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 5/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.62 |
| ▸ | HTR2A | P28223 | 4/20 | 0.62 |
| ▸ | SCN1A | P35498 | 4/20 | 0.62 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.62 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.62 |
| ▸ | HRH2 | P25021 | 3/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbinoxamine SCHEMBL29414093 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL29881788 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Rotoxamine SCHEMBL29485023 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL5070 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL8709373 | 0.99 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL662375 | 0.96 | CHRM2 (0.93) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL6626762 | 0.95 | CHRM2 (0.91) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL9095143 | 0.95 | CHRM2 (0.91) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL17685697 | 0.92 | CHRM2 (0.84) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL4074917 | 0.91 | CHRM2 (0.83) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106831549-B | A kind of method of asymmetric synthesis of Claritin carbinoxamine | 三峡大学 | 2019-03-15 | — | — | CN | claimed |
| CN-106831549-A | A kind of method of asymmetric synthesis of Claritin carbinoxamine | 三峡大学 | 2017-06-13 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0817794-A1 | METHOD FOR PROTEIN FOLDING | Bohr, Jakob (DK) | 1998-01-14 | — | — | EP | claimed |
| WO-1996030394-A1 | METHOD FOR PROTEIN FOLDING | BOHR JAKOB (DK) | 1996-10-03 | — | — | WO | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-0245518-A1 | ISOFLAVONE DERIVATIVES, SALTS THEREOF, AND ONCOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1987-11-19 | — | — | EP | disclosed |
| US-4154105-A | Orientable temperature indicator device | MACKLEY FRANK H | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | HRH1 530/4885CHRM2 158/4885SLC6A2 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.